Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Marker Therapeutics (NASDAQ:MRKR) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Marker Therapeutics (NASDAQ:MRKR) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Marker Therapeutics (NASDAQ:MRKR) was downgraded by analysts at
Wall Str
Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.